Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-12-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于控股股东股权质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, the pledge period, the pledgee, and the impact on shareholding percentages. There is no financial report, earnings data, or management discussion. The document is a formal disclosure about a shareholder's share pledge, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledge status and does not fit into more specific categories like Major Shareholding Notification (MRQ) or Transaction in Own Shares (POS) since it concerns pledged shares, not share ownership changes or buybacks. The document length is short (1529 characters), and it is a standalone announcement without financial statements or report attachments.
2018-12-25 Chinese
关于部分高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the increase in shareholding by a senior management member (the Vice General Manager) of the company. It details the number of shares purchased, the method of purchase, and compliance with relevant laws and regulations. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on this insider share purchase disclosure.
2018-12-25 Chinese
关于部分高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the increase in shareholdings by certain senior management personnel of the company. It details the names, positions, share quantities before and after the increase, and the purpose of the share purchases. There is no financial report, earnings data, or regulatory certification. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on shareholding changes by directors and senior management, confirming it is not a full financial report or other type of filing.
2018-12-23 Chinese
关于氯吡格雷拟中选4+7城市药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the company's proposed selection in the "4+7" city centralized drug procurement. It details the product involved, procurement quantities, pricing, and the procurement process timeline. The document is short (1193 characters) and primarily serves to inform investors and the public about a business development related to procurement and sales contracts. It does not contain financial statements, audit information, or detailed financial analysis. It is not a report but an announcement of a business event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-12-07 Chinese
关于获得替格瑞洛片药品补充申请批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a supplementary drug application for a new specification (60mg) of the drug Ticagrelor tablets. It includes details about the drug, regulatory approval, and potential impact on the company's business. The document is short (999 characters) and is an announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2018-12-04 Chinese
第四届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 4th Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details decisions regarding the acquisition of exclusive licensing rights and investment in a subsidiary, including authorization of company executives to execute related legal documents. The document is titled as a 'Board Meeting Resolution Announcement' and includes phrases like 'meeting resolutions' and 'board meeting decisions.' It does not contain financial statements, audit information, or detailed financial results. It is not a report or presentation but an official announcement of board decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a formal announcement of board decisions, not a report itself, so it is not an Annual Report or Management Report. Hence, the classification is MANG with high confidence.
2018-11-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.